InnoSerからのニュースと最新情報

Morris Water Maze, Rotarod and beyond: How do you build a comprehensive behavioral test battery when outsourcing your preclinical Alzheimer’s disease efficacy study?

Aug 13, 2026 | Blog, Neurology

A practical introduction to behavioural test battery selection when outsourcing your Alzheimer's disease efficacy study to a specialist neurology CRO When outsourcing a preclinical Alzheimer's disease efficacy study, behavioral endpoint selection is one of the most...

InnoSer Adds Regulatory Immunotoxicology Expertise with Acquisition of GLP-certified German CRO Vivo Science

Aug 3, 2026 | News

InnoSer International now offers sponsors a single, flexible partner across the full preclinical path, from early feasibility testing through GLP-compliant, submission-ready data. The addition of Vivo Science's expertise reflects InnoSer's ongoing strategy of...

STXBP1 Foundation and InnoSer validate R122X, a patient-variant mouse model of STXBP1 encephalopathy, to help expand therapeutic opportunities in STXBP1 research

Jul 14, 2026 | Neurology

Gene therapies, antisense oligonucleotides (ASOs), RNA editing technologies, and other precision medicine approaches are rapidly transforming the therapeutic landscape for STXBP1 encephalopathy. Currently, around 16 candidate therapies are in development across five...

Cognitive profiling in the APP[V717I]xTau[P301S] mouse model

Jul 3, 2026 | Neurology, Newsletter

In this month's update, we revisit the APP[V717I]xTau[P301S] model with newly in-house generated Morris Water Maze (MWM) data, reconfirming the spatial memory deficits previously described for this model and reinforcing the translational value of the model.The...